FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA Adds Several Peptides to Category 2 Bulks List, Restricting Them From Compounding Restore Health Consulting FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA considers adding a dozen peptides to its bulk drug compounding list RAPS